Cited 0 times in Scipus Cited Count

Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.

DC Field Value Language
dc.contributor.authorJin, SM-
dc.contributor.authorPark, CY-
dc.contributor.authorCho, YM-
dc.contributor.authorKu, BJ-
dc.contributor.authorAhn, CW-
dc.contributor.authorCha, BS-
dc.contributor.authorMin, KW-
dc.contributor.authorSung, YA-
dc.contributor.authorBaik, SH-
dc.contributor.authorLee, KW-
dc.contributor.authorYoon, KH-
dc.contributor.authorLee, MK-
dc.contributor.authorPark, SW-
dc.date.accessioned2017-02-01T05:15:43Z-
dc.date.available2017-02-01T05:15:43Z-
dc.date.issued2015-
dc.identifier.issn1462-8902-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/13442-
dc.description.abstractWe aimed to compare the efficacy and safety of lobeglitazone and pioglitazone as add-ons to metformin in patients with type 2 diabetes. Patients who were inadequately controlled by metformin were randomized and treated once daily with either lobeglitazone (0.5 mg, n = 128) or pioglitazone (15 mg, n = 125) for 24 weeks, with a 28-week extension trial of lobeglitazone treatment in patients who consented. The primary endpoint was the change in glycated haemoglobin (HbA1c) concentration from baseline to week 24. At week 24, the mean change from baseline in HbA1c was -0.74% for the lobeglitazone group and -0.74% for the pioglitazone group, with a mean difference of 0.01% [95% confidence interval (CI) of difference, -0.16 to 0.18]. The effects of lobeglitazone on lipid variables and the adverse events associated with lobeglitazone were similar to those observed with pioglitazone. Lobeglitazone was not inferior to pioglitazone as an add-on to metformin in terms of their efficacy and safety.-
dc.language.isoen-
dc.subject.MESHAged-
dc.subject.MESHBlood Glucose-
dc.subject.MESHDiabetes Mellitus, Type 2-
dc.subject.MESHDouble-Blind Method-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHFasting-
dc.subject.MESHFemale-
dc.subject.MESHHemoglobin A, Glycosylated-
dc.subject.MESHHumans-
dc.subject.MESHHypoglycemic Agents-
dc.subject.MESHInsulin Resistance-
dc.subject.MESHLipids-
dc.subject.MESHMale-
dc.subject.MESHMetformin-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPyrimidines-
dc.subject.MESHThiazolidinediones-
dc.titleLobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.-
dc.typeArticle-
dc.identifier.pmid25580775-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024060/-
dc.contributor.affiliatedAuthor이, 관우-
dc.type.localJournal Papers-
dc.identifier.doi10.1111/dom.12435-
dc.citation.titleDiabetes, obesity & metabolism-
dc.citation.volume17-
dc.citation.number6-
dc.citation.date2015-
dc.citation.startPage599-
dc.citation.endPage602-
dc.identifier.bibliographicCitationDiabetes, obesity & metabolism, 17(6). : 599-602, 2015-
dc.identifier.eissn1463-1326-
dc.relation.journalidJ014628902-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
Files in This Item:
25580775.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse